Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Glutathione synthetase deficiency is characterized by hemolytic anemia, associated with metabolic acidosis and 5-oxoprolinuria in moderate forms, and with progressive neurological symptoms and recurrent bacterial infections in the most severe forms.
Features include very common findings: Nervous system problems (abnormality of the nervous system), Red blood cell destruction (hemolytic anemia), Chronic metabolic acidosis, and Reduced glutathione synthetase level and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 1 | Nervous system problems (abnormality of the nervous system) |
Biomarker and diagnostic research for inherited glutathione synthetase deficiency has been reported in the published literature.
Phenotype severity distribution: 5 very common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
11 publications have been identified in PubMed for inherited glutathione synthetase deficiency. Research spans Case Report / Case Series (55%), Gene Therapy / Novel Therapeutics (18%), and Diagnostic / Biomarker (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 55% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:51 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Blood and immune system |
1 |
Red blood cell destruction (hemolytic anemia) |
Metabolism | 1 | Chronic metabolic acidosis |
New treatment approaches |
2 |
18% |
Testing and diagnosis research | 1 | 9% |
Research summaries | 1 | 9% |
Disease patterns and progression | 1 | 9% |
Demirsu A (2026). [PMID: 41204648](https://pubmed.ncbi.nlm.nih.gov/41204648/). *Journal of pediatric endocrinology & metabolism : JPEM*. [Case Report / Case Series]
Suresh Kumar Bindu BN (2026). [PMID: 41500709](https://pubmed.ncbi.nlm.nih.gov/41500709/). *BMJ case reports*. [Epidemiology / Natural History]
Koseci B (2026). [PMID: 41675684](https://pubmed.ncbi.nlm.nih.gov/41675684/). *Molecular syndromology*. [Case Report / Case Series]
Huang XW (2026). [PMID: 41452423](https://pubmed.ncbi.nlm.nih.gov/41452423/). *World journal of pediatrics : WJP*. [Diagnostic / Biomarker]
Nemoto H (2026). [PMID: 41469313](https://pubmed.ncbi.nlm.nih.gov/41469313/). *Pediatrics and neonatology*. [Gene Therapy / Novel Therapeutics]
Majtan T (2025). [PMID: 40495464](https://pubmed.ncbi.nlm.nih.gov/40495464/). *Molecular and cellular biology*. [Gene Therapy / Novel Therapeutics]
Locham J (2025). [PMID: 40697680](https://pubmed.ncbi.nlm.nih.gov/40697680/). *Medical journal, Armed Forces India*. [Case Report / Case Series]
Kasapkara ÇS (2024). [PMID: 39129838](https://pubmed.ncbi.nlm.nih.gov/39129838/). *Molecular syndromology*. [Review / Meta-Analysis]
Al-Saedi Z (2024). [PMID: 39776741](https://pubmed.ncbi.nlm.nih.gov/39776741/). *Cureus*. [Case Report / Case Series]
See AYS (2024). [PMID: 39114848](https://pubmed.ncbi.nlm.nih.gov/39114848/). *Clinical case reports*. [Case Report / Case Series]